Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

INTRODUCTION:Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to Asian populations in which such mutations are mor...

Full description

Bibliographic Details
Main Authors: Jacques De Grève, Jan Van Meerbeeck, Johan F Vansteenkiste, Lore Decoster, Anne-Pascale Meert, Peter Vuylsteke, Christian Focan, Jean-Luc Canon, Yves Humblet, Guy Berchem, Benoit Colinet, Danny Galdermans, Lionel Bosquée, Joanna Vermeij, Alex Dewaele, Caroline Geers, Denis Schallier, Erik Teugels
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4816447?pdf=render

Internet

http://europepmc.org/articles/PMC4816447?pdf=render

Similar Items